NEW YORK (GenomeWeb News) – Qiagen today announced its intent to acquire molecular diagnostics firm Ipsogen for €70 million ($101 million).
Qiagen has entered into exclusive negotiations with a group of Ipsogen shareholders to purchase about 47 percent of the company's outstanding shares currently held or controlled by company co-founders and board members. After the purchase agreement has been signed and the purchase is completed, Qiagen will begin to acquire all remaining shares of Ipsogen.
Qiagen is paying €12.90 per share to acquire a 47 percent stake in the company and to purchase all remaining shares afterward. The price represents a 71 percent premium to Ipsogen's share price of €7.53 per share on June 13, the last trading day before the deal was announced.
To read the full, original article click on this link: Qiagen Plans to Buy Cancer MDx Firm Ipsogen for $101M | GenomeWeb Daily News | DxPGx | GenomeWeb
